On 2015 May 12, David Gortler commented:

This trial supports the findings of the older CARDS trials which also showed that "lower is better" when it comes to LDL, and there is additive benefit to driving LDL levels beyond 70mg/dL (the current NECP goal) to even as low as 40mg/dL. Since this publication, it has been additionally shown that elevation of hsCRP is associated with increased risk of type 2 diabetes development in patients with all levels of metabolic syndrome.

In type 1 and type 2 diabetes mellitus, hemoglobin A1c significantly correlates with hsCRP levels and future cardiovascular risk indicating that diabetes has inflammatory fundamentals. Also, hsCRP levels increase with the stage of beta-cell dysfunction and insulin resistance. Non-diabetic drugs that have been shown to reduce hsCRP concentrations include aspirin, statins, cyclooxygenase-2 inhibitors, and fibrates.

On 2015 May 12, David Gortler commented:

This trial supports the findings of the older CARDS trials which also showed that "lower is better" when it comes to LDL, and there is additive benefit to driving LDL levels beyond 70mg/dL (the current NECP goal) to even as low as 40mg/dL. Since this publication, it has been additionally shown that elevation of hsCRP is associated with increased risk of type 2 diabetes development in patients with all levels of metabolic syndrome.

In type 1 and type 2 diabetes mellitus, hemoglobin A1c significantly correlates with hsCRP levels and future cardiovascular risk indicating that diabetes has inflammatory fundamentals. Also, hsCRP levels increase with the stage of beta-cell dysfunction and insulin resistance. Non-diabetic drugs that have been shown to reduce hsCRP concentrations include aspirin, statins, cyclooxygenase-2 inhibitors, and fibrates.